Sun Pharma Advanced Research Company Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Sun Pharma Advanced Research Company Ltd. on BSE

Load latest

Sun Pharma Advanced Research Company Ltd.

15 Apr 2019

146.50

2.08%

Corp. Note

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Statement Of Investor Complaints For The Quarter Ended March 2019

BSE India

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Debashis DeyDesignation :- Company Secretary and Compliance Officer

Sun Pharma Advanced Research Company Ltd.

03 Apr 2019

146.50

2.08%

Corp. Note

Sun Pharma Advanced Research Company Ltd - 532872 - Closure of Trading Window

BSE India

This is to inform you that, in compliance with the requirements of revised clause 4 of Schedule B to the SEBI (Prohibition of Insider Trading) Regulations, 2015 and in light of the clarifications issued under BSE Circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019 and NSE letter no. NSE/CML/2019/11 dated 2nd April, 2019, the Trading Window for trading by Designated Persons of the Company shall be closed with effect from tomorrow i.e. Thursday, 4th April 2019 till 48 hours after the declaration of financial results of the Company for the Quarter and Year ended 31st March 2019. The date of Board Meeting for declaration of the financial results for the Quarter and Year ended on 31st March 2019 will be intimated in due course.

pdf

Sun Pharma Advanced Research Company Ltd.

29 Mar 2019

146.50

2.08%

Corp. Note

Sun Pharma Advanced Research Company Ltd - 532872 - Announcement under Regulation 30 (LODR)-Code of Conduct …

BSE India

In compliance with the regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended ('the Regulations') we enclose herewith the revised 'Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information', adopted by the Company under regulation 8(1) of the Regulations which shall be effective from 1st April 2019.

pdf

Sun Pharma Advanced Research Company Ltd.

26 Mar 2019

146.50

2.08%

Corp. Note

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Disclosures under Reg. 31(1) and 31(2) of …

BSE India

The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pratham Investments

pdf

Sun Pharma Advanced Research Company Ltd.

13 Mar 2019

146.50

2.08%

Corp. Note

Sun Pharma Advanced Research Company Ltd - 532872 - Announcement under Regulation 30 (LODR)-Press Release / …

BSE India

Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we enclose herewith the Press Release on ''SPARC Announces research collaboration with HitGen Limited, a Chinese company, to identify and discover novel small molecule leads for SPARC'' being released by the Company, which is self-explanatory. We request you to kindly take the same on record.

pdf

Sun Pharma Advanced Research Company Ltd.

12 Mar 2019

146.50

2.08%

Corp. Note

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg. 39 (3) - Details of Loss …

BSE India

Dear Sir/Madam, Pursuant to regulation 39(3) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform you that the share certificate(s) as per attached details, issued by Sun Pharma Advanced Research Company Limited, have been reported by the registered shareholder(s)/ bona fide purchasers to have been lost/ misplaced/stolen. We request you to kindly take the same on record.

pdf

Sun Pharma Advanced Research Company Ltd.

02 Mar 2019, 11:40AM

146.50

2.08%

Corp. Note

Sun Pharma Advanced Research Company Ltd - 532872 - Compliances-Reg. 39 (3) - Details of Loss …

BSE India

Dear Sir/Madam, Pursuant to regulation 39(3) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform you that the share certificate(s) as per details attached, issued by Sun Pharma Advanced Research Company Limited, have been reported by the registered shareholder(s)/ bona fide purchasers to have been lost/ misplaced/stolen. We request you to kindly take the same on record.

pdf

Sun Pharma Advanced Research Company Ltd.

15 Feb 2019

146.50

2.08%

Corp. Note

Sun Pharma Advanced Research Company Ltd - 532872 - Return Of Product Rights By Partner For …

BSE India

Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform that we have received a communication from Sun Pharma Global FZE (SPGFZE), a wholly owned subsidiary of Sun Pharmaceutical Industries Limited, informing us that SPGFZE is not planning to launch ElepsiaTM XR (Levetiracetam Extended-Release Tablets) as CNS is not its focussed therapeutic area in US market, and therefore SPGFZE has decided to return the product rights back to SPARC. SPARC had out-licensed ELEPSIATM XR to SPGFZE in July 2016; and was eligible for sales linked milestone and royalties upon commercialization of Elepsia TM XR. Consequently, SPARC would find another partner for commercialising the captioned product.

pdf

Sun Pharma Advanced Research Company Ltd.

07 Feb 2019

146.50

2.08%

Corp. Note

Sun Pharma Advanced Research Company Ltd - 532872 - Receipt Of Demand Order From The Office …

BSE India

Pursuant to regulation 30 (1) of the SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we hereby inform you that the Company is receipt of an 'Order' from the Office of the Commissioner of GST & Central Excise, Mumbai East Commissionerate, demanding the payment of Service Tax along with Penalty aggregating to Rs. 46.04 crores along with interest under section 75 of the Finance Act, 1994. The Company would contest the demand and would be filing an appropriate appeal against the Order within the stipulated period. This is for your information and public dissemination.

pdf

Sun Pharma Advanced Research Company Ltd.

04 Feb 2019

146.50

2.08%

Corp. Note

Sun Pharma Advanced Research Company Ltd - 532872 - Outcome of Board Meeting

BSE India

The Board of Directors of the Company at their meeting held from 12:15 pm to 04:00 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter and nine months ended 31st December 2018 which is enclosed herewith along with the Limited Review Report of the Statutory Auditors thereon as Annexure I. This is for your information and record.

pdf

Is Sun Pharma Advanced Research Company Ltd. worth buying?

207 Votes:

Buy 71.98%

Sell 19.81%

Hold 8.21%